Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chest pain, Eyelid irritation, Nausea, Vision blurred
Clinical narrative: heart area/chest pain, sometime dull sometimes sharp pain and discomfort; heart area/chest pain, sometime dull sometimes sharp pain and discomfort; nausea; blurry vision developed and lasted for 2 weeks; felt very heavy impurity inside of upper eyelid; This is a spontaneous report received from contactable reporter (Consumer or other non-HCP). The reporter is the patient.  A 54 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 12Jan2022 10:30 (Lot number: FL3197) at the age of 54 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing), notes: other medical history: asthma; "sulfite" (unspecified if ongoing), notes: known allergies: sulfite. Concomitant medication(s) included: PULMICORT. Past drug history included: Aspirin, reaction(s): "Allergy: aspirin", notes: known allergies: aspirin; Penicillin, reaction(s): "allergies: penicillin", notes: known allergies: penicillin. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6208, Location of injection: Arm Left, Vaccine Administration Time: 11:00 AM), administration date: 17Mar2021, when the patient was 53 years old, for Covid-19 Immunization, reaction(s): "heart area/chest pain, sometime dull sometimes sharp pain and discomfort ", "nausea"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0150, Location of injection: Arm Left, Vaccine Administration Time: 11:00 AM), administration date: 12Apr2021, when the patient was 53 years old, for Covid-19 Immunization, reaction(s): "heart area/chest pain, sometime dull sometimes sharp pain and discomfort ", "nausea". The following information was reported: CHEST PAIN (non-serious), CHEST DISCOMFORT (non-serious) all with onset 13Jan2022, outcome "recovered with sequelae" and all described as "heart area/chest pain, sometime dull sometimes sharp pain and discomfort"; NAUSEA (non-serious) with onset 13Jan2022, outcome "recovered with sequelae", described as "nausea"; VISION BLURRED (non-serious) with onset 13Jan2022, outcome "recovered with sequelae", described as "blurry vision developed and lasted for 2 weeks"; EYELID IRRITATION (non-serious) with onset 13Jan2022, outcome "recovered with sequelae", described as "felt very heavy impurity inside of upper eyelid". Therapeutic measures were not taken as a result of chest pain, chest discomfort, nausea, vision blurred, eyelid irritation.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. List of any other medications the patient received within 2 weeks of vaccination included ProAir Inhaler sometimes. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Device Date: 30Jan2022. It was reported that the patient experienced heart area/chest pain, sometime dull sometimes sharp pain and discomfort with nausea in all 3 stages of vaccine. In 3rd vaccine there were more symptom with her eyesight. She had blurry vision developed and lasted for 2 weeks. She felt very heavy impurity inside of upper eyelid. Adverse event resulted in none of the above. The reporter assessed the case as non-serious with no seriousness criteria of resulting in death, Life threatening, Caused/prolonged hospitalization, Disabling/Incapacitating, Congenital anomaly/birth defect.  Follow-up attempts are completed. No further information is expected.